Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy

NCT01744912 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT01744912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01744912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 21, 2012
Completion date
February 7, 2014
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphomas, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone lymphoma, non-hodgkins lymphoma, small lymphocytic lymphoma, waldenstrom's macroglobulinemia